Temsirolimus and Metastases to bone - a phase IV clinical study of FDA data

Summary:

Metastases to bone is reported as a side effect among people who take Temsirolimus (temsirolimus), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Zometa, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have Metastases to bone when taking Temsirolimus. It is created by eHealthMe based on reports of 3,570 people who have side effects when taking Temsirolimus from the FDA, and is updated regularly.

What is Temsirolimus?

Temsirolimus has active ingredients of temsirolimus. eHealthMe is studying from 3,573 Temsirolimus users. Check the latest studies of Temsirolimus.

What is Metastases to bone?

Metastases to bone (cancer spreads to bone) is found to be associated with 1,127 drugs and 902 conditions by eHealthMe. Check the latest studies of Metastases to bone.

On Jul, 12, 2026

3,570 people reported to have side effects when taking Temsirolimus.
Among them, 29 people (0.81%) have Metastases to bone.

Could Temsirolimus cause Metastases to bone?

Among these 29 people:

How long have people been on Temsirolimus when they have Metastases to bone? *

What is the gender of people who have Metastases to bone when taking Temsirolimus? *

female: 13.79 %
male: 86.21 %

What is the age of people who have Metastases to bone when taking Temsirolimus? *

What are other drugs people take besides Temsirolimus? *

What are other side effects people have besides Metastases to bone? *

Pleural Effusion (water on the lungs): 25 people, 86.21%
Anaemia (lack of blood): 23 people, 79.31%
Constipation: 23 people, 79.31%
Injury: 22 people, 75.86%
Stress And Anxiety: 22 people, 75.86%
Pain: 22 people, 75.86%
Fatigue (feeling of tiredness): 20 people, 68.97%
Fever: 18 people, 62.07%
Lymphadenopathy Mediastinal (an enlargement of the lymph nodes in the part of the chest that separates the lungs): 18 people, 62.07%
Metastases To Central Nervous System (cancer spreads to central nervous system): 18 people, 62.07%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 13 people, 44.83%
Bone Density Decreased: 11 people, 37.93%
Pain: 11 people, 37.93%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 11 people, 37.93%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 7 people, 24.14%
High Blood Pressure: 4 people, 13.79%
Renal Cell Carcinoma (a kidney cancer): 2 people, 6.90%
Bone Disorder: 1 person, 3.45%
Bone Loss: 1 person, 3.45%
Breast Cancer: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Temsirolimus and have Metastases to bone?

- Check whether Metastases to bone is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Temsirolimus:

Temsirolimus (3,573 reports)

Browse all side effects of Temsirolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Metastases to bone:

Metastases to bone (1,127 drugs)

Browse all the conditions that are associated with Metastases to bone:

Metastases to bone (902 conditions)

Related publications that referenced our studies

Herrin MA, Rubinstein JC, Christison-Lagay ER, "Temsirolimus therapy and small bowel perforation in a pediatric patient with Clostridium septicum bacteremia", Journal of Pediatric Surgery Case Reports, 2015 Aug .
Herrin MA, Rubinstein JC, Christison-Lagay ER, "Temsirolimus therapy and small bowel perforation in a pediatric patient with Clostridium septicum bacteremia", Journal of Pediatric Surgery Case Reports, 2015 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on temsirolimus (the active ingredients of Temsirolimus) and Temsirolimus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.